We’re once again looking forward to joining the biopharma community at the 42nd Annual J.P. Morgan in January 2024. Members of the Mogrify team, including CEO, Darrin M Disley, and Chief of Staff, Mark Cavanagh, will be on hand to navigate you through the latest advancements across the MOGRIFY® direct reprogramming platform and the anticipated development milestones in each of our therapeutic programs over the next 6-12 months.
Connect via BIO Partnering or email us at [email protected] to arrange a catch-up.